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Abstract 26 
Methicillin-resistant Staphylococcus aureus (MRSA) is infrequently reported in mastitis. Yet, 27 
as in many other countries, the prevalence of methicillin resistance among S. aureus from 28 
mastitis is currently unknown in Belgium.  29 
To elucidate this, the presence of mecA was investigated in 118 S. aureus strains originating 30 
from diagnostic mastitis milk samples from 118 different farms experiencing S. aureus 31 
mastitis. MRSA strains were characterized by disk diffusion susceptibility testing, spa-typing, 32 
MLST and SCCmec-typing. In an additional study, four MRSA-positive farms were selected 33 
to assess the in-herd prevalence of MRSA, by sampling all cows in lactation. Isolated MRSA 34 
strains were similarly characterized.  35 
The mecA gene was detected in eleven (9.3%) of the 118 S. aureus isolates, indicating that 36 
nearly 10% of the Belgian farms suffering from S. aureus mastitis have an MRSA problem. 37 
The in-herd prevalence varied between 0% and 7.4%. Characterization of the MRSA strains 38 
showed that they were all resistant to tetracycline. Additional resistances to macrolides, 39 
lincosamides and aminoglycosides were frequently detected. The strains were ST398, spa-40 
types t011 or t567 and had SCCmec-types IVa or V, proving they belong to the emerging 41 
livestock-associated MRSA (LA-MRSA) strains of CC398. 42 
Our study shows that after detection in Belgian pigs, horses and poultry, LA-MRSA has also 43 
attained Belgian cattle. It is the first report on frequent isolation of LA-MRSA from bovine 44 
infections. As the in-herd isolation rate resembles that of regular S. aureus in farms 45 
experiencing S. aureus mastitis, the multi-resistance of LA-MRSA strains may cause future 46 
treatment problems. 47 
Keywords 48 
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Introduction 51 
Staphylococcus aureus is a major pathogen in dairy cattle mastitis (Waage et al., 1998; 52 
Tenhagen et al., 2006; Piepers et al., 2007). Resistance of S. aureus to antimicrobial agents 53 
can complicate treatment of its infections (Lowy, 2003). For treatment of mastitis, methicillin 54 
resistance, which is caused by the expression of the mecA gene, is of particular interest. 55 
Indeed, this mechanism confers resistance to almost all types of β-lactam antibiotics active 56 
against S. aureus, and these antibiotics are still frequently used in mastitis treatment (Sawant 57 
et al., 2005). However, methicillin-resistant Staphylococcus aureus (MRSA) has never been  58 
important in mastitis. After the very first report of MRSA in mastitis in 1972 (Devriese et al., 59 
1972), MRSA has been described in mastitis only occasionally (Lee, 2003; Kwon et al., 2005; 60 
Lee, 2006; Juhász-Kaszanyitzky et al., 2007; Moon et al., 2007; Hendriksen et al., 2008). 61 
From such studies, it seems that the prevalence of MRSA in mastitis is generally low. Yet, 62 
data on MRSA in mastitis need to be assessed carefully, as there are often ambiguities on 63 
presence of mecA, level of investigation and origin of the detected MRSA strains. 64 
Recently, a specific MRSA clone, CC398, has been found associated with pigs, veal calves, 65 
broiler chickens, companion animals and people in close contact with livestock. MRSA of this 66 
type, called Livestock-Associated MRSA (LA-MRSA), typically has closely related spa-types 67 
(de Neeling et al., 2007; Denis et al., 2009), carries mostly SCCmec-types IVa and V (Witte et 68 
al., 2007; Van den Eede et al., 2009) and cannot be typed with PFGE using SmaI digestion 69 
(Bens et al., 2006). In addition, LA-MRSA shows resistance against tetracycline and, to a 70 
lesser extent, macrolides, lincosamides, aminoglycosides and fluoroquinolones (Witte et al., 71 
2007). Generally LA-MRSA lacks common virulence factors found in other MRSA 72 
(Monecke et al., 2007; Walther et al., 2009). This is remarkable because, although 73 
infrequently compared to colonization, LA-MRSA has been isolated from infections, of both 74 
animals and humans (e.g. Hermans et al., 2008; Krziwanek et al., 2009). To our knowledge, 75 
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so far only one study has reported on the isolation of MRSA ST398 from a case of mastitis 76 
(Monecke et al., 2007).  77 
We performed two studies to assess the role of MRSA in Belgian S. aureus mastitis. In a first 78 
study we investigated how many S. aureus isolated from mastitis were resistant to methicillin. 79 
Second, we investigated the in-herd prevalence of MRSA in Belgian herds where cows were 80 
previously shown to suffer from MRSA mastitis. 81 
Methods 82 
1. Methicillin resistance in S. aureus isolated from mastitis 83 
Strains 84 
From November 2006 through April 2007, the regional veterinary laboratories were asked to 85 
send us a representative isolate from all farms on which an S. aureus-mastitis problem was 86 
detected. Care was taken to include only one strain per visited farm. As such, a collection of 87 
118 non duplicate isolates of S. aureus, originating from cases of subclinical or clinical 88 
mastitis from different farms was obtained.  89 
DNA extraction 90 
An Eppendorf cup (Eppendorf, Germany) containing a 500 µl Brain Heart Infusion broth 91 
(BHI) (BioRad, France) overnight pure culture was centrifuged for 3.0 min at approx. 92 
20,000 x g, at room temperature. After removal of the supernatant, 45 µL of sterile, distilled 93 
water and 5 µL of a 1 mg/mL lysostaphin (Sigma-Aldrich, USA) solution at 4°C were 94 
thoroughly mixed with the pellet of cells. After incubation for 10 min at 37°C, 45 µL of 95 
sterile, distilled water, 5 µL of a 2 mg/mL proteïnase K (Merck, Germany) solution at 4°C 96 
and 150 µL of tris-HCl of 0.1 M at pH 8.0 were added. The resulting solution was incubated 97 
for 10 min at 60°C, followed by 5 min at 100°C and then centrifuged for 5 min at approx. 98 
20,000 x g, at room temperature. DNA was stored at -20°C until use. 99 
Identification of MRSA 100 
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A triplex PCR, targeting a Staphylococcus-specific 16S rRNA sequence, the mecA gene and 101 
the S. aureus specific region of the thermonuclease gene (nuc), was performed as previously 102 
described (Maes et al., 2002). The amplified DNA fragments were separated by 103 
electrophoresis on a 2% agarose (Sigma-Aldrich, USA) gel stained with SYBR Safe DNA gel 104 
stain (Invitrogen, USA), for 2 h at 80V, using an O’RangeRuler 100bp DNA ladder 105 
(Fermentas, Germany).  106 
Characterization of MRSA 107 
Susceptibility testing 108 
Strains proven to be MRSA were tested for susceptibility to non β-lactam antimicrobial 109 
agents, by using the disk diffusion method. A panel of 16 antimicrobial agents was used: 110 
chloramphenicol, gentamicin, kanamycin, tobramycin, fucidic acid, erythromycin, tylosin, 111 
lincomycin, linezolid, quinupristin + dalfopristin, mupirocin, ciprofloxacin, tetracycline, 112 
rifampicin, sulfonamides and trimethoprim (NeoSensitabs, Rosco, Denmark). Results were 113 
recorded after 24h incubation at 37°C and interpreted according to the directions for use of 114 
Rosco with the method described by the CLSI guidelines (document M31-A3). 115 
Spa-typing 116 
Of all MRSA strains, the polymorphic X-region of the Staphylococcus protein A (spa) gene 117 
was amplified according to the Ridom StaphType standard protocol 118 
(www.ridom.de/staphtype). Amplicons were purified with a Nucleospin Extract II kit 119 
(Macherey-Nagel, Germany) and then sequenced using the same primers. The sequenced 120 
DNA was then run on a CEQ 8000 Genetic Analysis System (Beckman Coulter, United 121 
Kingdom) according to the manufacturer’s instructions. The resulting spa-types were assigned 122 
by using the Ridom StaphType software package (Ridom GmbH, Germany). 123 
MLST 124 
Multi Locus Sequence Typing was performed on all MRSA strains. In short, seven household 125 
genes of S. aureus were amplified using primers previously described (Enright et al., 2000). 126 
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Amplicons were purified with a Nucleospin Extract II kit (Macherey-Nagel, Germany) and 127 
then sequenced using the same primers. The sequenced DNA was then run on a CEQ 8000 128 
Genetic Analysis System (Beckman Coulter, United Kingdom) according to the 129 
manufacturer’s instructions. Allele numbers and sequence type (ST) were assigned by using 130 
the S. aureus MLST website (http://saureus.mlst.net).  131 
SCCmec-typing 132 
The SCCmec type was determined using three different sets of primers (Oliveira and de 133 
Lencastre, 2002; Zhang et al., 2005; Milheiriço et al., 2007). For differentiation among 134 
SCCmec types I–IV we used all the primers described by Oliveira and de Lencastre (2002). 135 
The PCR mix consisted of 25 µL of Taq PCR Master Mix (Qiagen Gmbh, Germany), 4 µL of 136 
H2O and 16 µL of the primers, in the reported concentration. To this mix 5 µL DNA was 137 
added.  138 
For subtyping SCCmec of type IV, we used the primers described by Milheiriço et al. (2007). 139 
The PCR-mix consisted of 25 µL of Taq PCR Master Mix (Qiagen Gmbh, Germany), 6.4 µL 140 
of H2O, 0.2 µM of primers J IVa forward (F) and reverse (R), 0.2 µM of J IVb F and R, 0.4 141 
µM of ccr B2 F and J IVc F and R, 0.8 µM of ccrB2 R, J IVd F and R, 0.9 µM of J IVg F and 142 
R, and 0.9 µM of J IVh F and R. To the mix 5 µL DNA was added.  143 
A third set, meant to detect SCCmec-type V and to have a control for SCCmec-types IVb, 144 
IVc, IVe and IVf, was based on the method described by Zhang et al. (2005). The PCR mix 145 
consisted of 25 µL of Taq PCR Master Mix (Qiagen Gmbh, Germany), 10.4 µL of H2O, 0.6 146 
µM of primers Type V F and R, 0.8 µM of Type IVc F and R, and 1.0 µM of Type IVb F and 147 
R. To the mix 5 µL DNA was added.  148 
We used the same PCR program for all three sets: an initial denaturation of 4 min at 94°C, 35 149 
cycles of denaturation at 94°C for 30 s, annealing at 53°C for 30 s and extension at 72°C for 150 
1 min, followed by a final extension for 4 min at 72°C. 151 
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2. MRSA in-herd prevalence 152 
From the results of the first study, four MRSA positive farms were selected for investigation 153 
of the in-herd prevalence of MRSA, defined as the number of MRSA-positive cows relative to 154 
the total number of lactating cows present in the specific farm. A randomly chosen fifth farm 155 
volunteered to serve as control (Table 2). Milk samples were taken from each quarter. All 156 
sampling was done by the same person, from February 2008 through April 2008.  157 
Samples were immediately transported to the Veterinary and Agrochemical Research Center 158 
(VAR), where each sample was plated on Columbia Colistine Aztreonam Plates (CAP) 159 
supplemented with 5% sheep blood (Oxoid, Germany) and on chromID MRSA plates 160 
(Biomérieux, France). Suspected S. aureus or MRSA colonies were purified. Pure colonies 161 
were then subjected to the MRSA triplex PCR, as described above. Strains identified as 162 
MRSA were characterized by susceptibility testing, spa-typing, MLST and SCCmec-typing, 163 
as described above. 164 
Results 165 
1 – Methicillin resistance in S. aureus isolated from mastitis  166 
Detection of MRSA 167 
All 118 isolates phenotypically identified as S. aureus were confirmed to be S. aureus by the 168 
triplex PCR. A total of 11 isolates (9.3%) contained mecA (Table 1). Two MRSA originated 169 
from clinical mastitis, the other nine from subclinical mastitis (Table 1).  170 
Antimicrobial susceptibility testing 171 
Antibiotic resistance patterns of the 11 MRSA strains are shown in Table 1. Nine of them 172 
showed additional resistance to at least two different antibiotics. All strains were resistant to 173 
tetracycline; nine were resistant to trimethoprim, seven to aminoglycosides and lincomycin, 174 
five to macrolides and two to ciprofloxacin (Table 1). No resistance was detected to the other 175 
antimicrobial agents tested.  176 
MLST, spa- and SCCmec-typing  177 
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Ten strains were spa-type t011. One strain had a different yet related spa-type, t567 (Table 1). 178 
All MRSA strains were ST398 (Table 1). Five strains had SCCmec-type IVa, and five had 179 
SCCmec-type V. The SCCmec-type of one strain could not be determined with the different 180 
sets of primers we used (Table 1). 181 
2 – MRSA in-herd prevalence  182 
Identification of MRSA 183 
The percentage of cows carrying MRSA in their milk varied between 0% and 7.4% (Table 2). 184 
Quarter level prevalence ranged from 0% to 1.98% (Table 2). Three of the four selected farms 185 
were positive. MRSA could not be detected in one farm previously found positive nor in the 186 
control farm (Table 2).  187 
One cow from the first farm carried MRSA in three of her quarters. In all other positive cows, 188 
MRSA was found in only one quarter, resulting in 14 isolates in total (Table 3). Most isolates 189 
were found in the right-hind (6 isolates) and right-front (4 isolates) quarter (Table 3). Of the 190 
11 cows that had MRSA in only one quarter, nine of the MRSA isolates were found in one of 191 
the hind-quarters. 192 
Antimicrobial susceptibility testing 193 
All six strains isolated from the first farm had the same susceptibility profile (Table 3). They 194 
were all resistant to tetracycline, the tested macrolides and lincomycin, and were susceptible 195 
to all other antimicrobial agents tested.  196 
In the second farm, two out of five strains were resistant to trimethoprim, tetracycline and the 197 
tested aminoglycosides, and susceptible to all other antimicrobial agents tested. The three 198 
other strains had additional resistances to the tested macrolides and lincomycin (Table 3). 199 
The three strains from the third farm were resistant to the tested aminoglycosides, macrolides, 200 
lincomycin, tetracycline and trimethoprim (Table 3). They were susceptible to the other 201 
antimicrobial agents tested.  202 
MLST, spa- and SCCmec-typing 203 
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All MRSA strains showed spa-type t011 (Table 3). The strains originating from the first farm 204 
had SCCmec type V, while all strains isolated from the cows of the other two farms had 205 
SCCmec type IVa (Table 3). MLST was performed on one representative MRSA strain per 206 
farm. As strains from farm 2 showed two different resistance profiles, one representative 207 
strain from each profile was tested. The four strains tested all were ST398 (Table 3).  208 
Discussion 209 
The prevalence of methicillin resistance in S. aureus isolated from mastitis in our first study is 210 
unexpectedly high. In the abundance of studies investigating the antibiotic resistance of 211 
mastitis pathogens, few reports have noted a substantial occurrence of methicillin resistance, 212 
meaning MRSA is usually negligible as a mastitis pathogen (Hendriksen et al., 2008). 213 
However, we found nearly 10% of our 118 S. aureus strains to be MRSA. This means that 214 
nearly 10% of the Belgian farms experiencing S. aureus mastitis is affected by MRSA.  215 
Reports can be found in which a higher prevalence of MRSA among S. aureus isolated from 216 
mastitis cases is described. In Turkey, Turutoglu et al. (2006) found 18 out of 103 (17.5%) S. 217 
aureus isolates from mastitis milk samples to be MRSA. However, they did not mention 218 
whether all strains were collected from different farms experiencing S. aureus mastitis. In 219 
addition, their detection method was limited to phenotypic disk diffusion testing. Performing 220 
only phenotypic tests has previously been shown to lead to false positive or false negative 221 
results (Murakami et al., 1991; De Oliveira et al., 1999). Generally it is now accepted that 222 
checking for the presence of mecA is the most reliable method for detection of methicillin 223 
resistance, and staphylococci carrying mecA should be regarded as resistant to almost all types 224 
of β-lactam antibiotics (CLSI guidelines, M31-A3). Consequently, to accurately assess our 225 
results, only other reports in which mecA was proven to be present should be considered. Still, 226 
even then, it remains difficult to make viable comparisons, due to differences in sampling 227 
methodology or a lack of information on the source of the strains. For example, two South 228 
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Korean studies did not mention exactly how many of their samples originated from mastitis 229 
(Lee, 2003; Lee, 2006). A Hungarian study sampled only a single farm (Juhász-Kaszanyitzky 230 
et al., 2007). In two other studies from South Korea, the data involved quarter-level results 231 
(Kwon et al., 2005; Moon et al., 2007). 232 
Despite these difficulties to fully assess our results, it must be acknowledged that the MRSA 233 
prevalence we found is quite high. However, some other remarks should be made. First, the 234 
burden of MRSA for Belgian milk production cannot be assessed, because we have no data on 235 
the total number of farms that were visited during the sampling period. Also, while our study 236 
allows us to estimate the importance of methicillin resistance in Belgian S. aureus mastitis, 237 
we cannot judge the importance of MRSA for mastitis as a whole. A hint to address the latter 238 
can be found in a recent study that investigated the importance of S. aureus in Belgian 239 
mastitis. It was found that S. aureus was the most prevalent species in Belgian quarter milk 240 
samples from subclinical mastitis, with 25% of culture-positive quarter samples with a 241 
geometric mean composite somatic cell count of ≥ 250 000 cells/ml harboring S. aureus 242 
(Piepers et al., 2007). Regarding this, our result is certainly quite worrying.  243 
Another important fact is presented by our typing data. All our strains had characteristics 244 
typical for the emerging livestock-associated MRSA CC398 strains. Consequently, it seems 245 
that our findings should rather be regarded as a further expansion of the host range of the 246 
CC398 MRSA clone than as an indication of a generally increasing incidence of methicillin 247 
resistance in mastitis-associated S. aureus. This should however not be less worrying.  248 
In addition to its resistance against all β-lactam antibiotics, which are still the most used 249 
antimicrobial agents in the treatment of mastitis, the typical antibiotic resistances of LA-250 
MRSA also include some other antibiotics used to treat or prevent mastitis, such as 251 
aminoglycosides and macrolides (Sawant et al., 2005). This could lead to serious treatment 252 
problems. Moreover, in our second study we found that the in-herd prevalence of LA-MRSA 253 
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ranged between 0% and 7.4%. In the farms where MRSA was found, it varied from 3.9% to 254 
7.4%, with a corresponding quarter level prevalence of 0.97% to 1.98%. This resembles the 255 
in-herd quarter level prevalence of S. aureus described earlier in a cross-sectional collection 256 
of Belgian milk samples (Piepers et al., 2007), suggesting that, considering its spread in 257 
farms, LA-MRSA behaves similar to regular mastitis causing S. aureus. The possibility that 258 
LA-MRSA could become equally important in mastitis as normal S. aureus should thus be 259 
thoroughly investigated. Unfortunately, we have no data on the individual health status of the 260 
cows from which MRSA was isolated in our second study, so we cannot state that the LA-261 
MRSA strains we found were actually involved in mastitis. As it was shown that within-cow 262 
transmission between quarters likely occurs in S. aureus mastitis (Barkema et al., 1997), the 263 
fact that 11 of the 12 cows carried LA-MRSA in only one quarter could mean that the isolates 264 
concerned only contaminants. However, S. aureus infection of only one quarter also certainly 265 
exists (Barkema et al., 1997). Moreover, S. aureus was shown to more frequently infect the 266 
right and hind quarters (Barkema et al., 1997; Barkema et al., 2006). Of the 11 single-quarter 267 
LA-MRSA isolates we found, 10 originated from right quarters and nine from hind quarters. 268 
Considering also our first study, which clearly showed the capacity of LA-MRSA to cause 269 
mastitis, the actual presence of LA-MRSA in Belgian mastitis should urgently be studied in 270 
more depth, in order to profoundly assess its possible burden. 271 
LA-MRSA has been reported only once before in mastitis in cows, one LA-MRSA strain that 272 
was found among 128 S. aureus isolated from German mastitis cases (Monecke et al., 2007). 273 
While this strain was spa-type t034, our strains were spa-types t011 and t567. It thus seems 274 
unlikely that a specific subclone of LA-MRSA is associated with mastitis, but more research 275 
is required to confirm this. Until now, it is also unclear whether LA-MRSA has an actual 276 
reservoir in dairy cattle. Whereas veal calves have been found carrying LA-MRSA in the 277 
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Netherlands (Mooij et al., 2007) and Belgium (unpublished data), the colonization capacity of 278 
LA-MRSA in milking cows has not yet been investigated.  279 
The presence of LA-MRSA in infections has been reported substantially less frequent than 280 
carriage, and has only been described occasionally in pigs (van Duijkeren et al., 2007), horses 281 
(Hermans et al., 2008; Loeffler et al., 2009), humans (e.g. Krziwanek et al., 2009) and a dog 282 
(Witte et al., 2007). Our findings thus seem to add new proof of a certain pathogenic potential 283 
of LA-MRSA. Remarkably, many common virulence factors, including those considered to 284 
be involved in mastitis, such as toxic shock syndrome toxin-1 (tsst-1), haemolysins and 285 
enterotoxins (Matsunaga et al., 1993), have been shown to be largely absent in LA-MRSA 286 
(Monecke et al., 2007; Walther et al., 2009). However, as we did not check for the presence of 287 
virulence factors in our strains, the significance of our data regarding the pathogenic potential 288 
of LA-MRSA is hard to assess. Yet, in addition to the other reports on LA-MRSA associated 289 
with infections, our findings urge for further research into the virulence capacities of LA-290 
MRSA. 291 
Conclusions 292 
We found an unusual high prevalence of MRSA in Belgian cases of subclinical and clinical S. 293 
aureus mastitis in cows. All strains belonged to the CC398 clone, which, seen its multi-294 
resistance, may lead to treatment problems. Future research is warranted to assess the actual 295 
spread and corresponding burden that LA-MRSA may pose for dairy cattle farming and to 296 
elucidate which virulence factors are involved. 297 
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Table 1. Resistance profile, Multi-Locus Sequence Type (MLST), spa- and Staphylococcal 418 
Cassette Chromosome (SCC)mec-type per MRSA strain in study 1. 419 
Strain Type of mastitis Resistance profilea spa  MLST SCCmecb 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
Subclinical 
Clinical 
Subclinical 
Subclinical 
Subclinical 
Subclinical 
Subclinical 
Clinical 
Subclinical 
Subclinical 
Subclinical 
AG, TET, TMP 
AG, TET, TMP 
AG, ML, LM, TET, TMP 
LM, CIP, TET, TMP 
TET 
AG, ML, LM, TET, TMP 
LM, CIP, TET, TMP 
AG, ML, LM, TET, TMP 
KAN, TOB, ML, LM, TET, TMP 
AG, ML, LM, TET, TMP 
TET 
t011 
t011 
t011 
t011 
t567 
t011 
t011 
t011 
t011 
t011 
t011 
398 
398 
398 
398 
398 
398 
398 
398 
398 
398 
398 
IVa 
IVa 
IVa 
V 
NT 
IVa 
V 
IVa 
V 
V 
V 
a
 AG: all aminoglycosides tested; KAN: kanamycin; TOB: tobramycin; ML: all macrolides 420 
tested; LM: lincomycin; CIP: ciprofloxacin; TET: tetracycline; TMP: trimethoprim 421 
b
 NT: not typeable with the primers used 422 
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Table 2. In-herd prevalence of MRSA • no. 5: control farm 423 
Positive cows Positive quarters Farm  Herd size 
(n cows) 
Herd size 
(n quarters) n % n % 
1 
2 
3 
4 
5 
63 
68 
77 
51 
69 
252 
272 
308 
204 
276 
4 
5 
3 
0 
0 
6.3 
7.4 
3.9 
0 
0 
6 
5 
3 
0 
0 
1.98 
1.83 
0.97 
0 
0 
 424 
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Table 3. Resistance profile, Multi-Locus Sequence Type (MLST), spa- and Staphylococcal 425 
Cassette Chromosome (SCC)mec-type per MRSA strain in study 2. 426 
Farm Quartera  Strain Resistance profileb Spa MLSTc SCCmec 
1 
LH 
RH 
RF 
LF 
RH 
RF 
1 
2 
3 
4 
5 
6 
ML, LM, TET 
ML, LM, TET 
ML, LM, TET 
ML, LM, TET 
ML, LM, TET 
ML, LM, TET 
t011 
t011 
t011 
t011 
t011 
t011 
ND 
ND 
ND 
398 
ND 
ND 
V 
V 
V 
V 
V 
V 
2 
LH 
LF 
RH 
RH 
RH 
7 
8 
9 
10 
11 
AG, TET, TMP 
AG, ML, LM, TET, TMP 
AG, TET, TMP 
AG, ML, LM, TET, TMP 
AG, ML, LM, TET, TMP 
t011 
t011 
t011 
t011 
t011 
398 
ND 
ND 
398 
ND 
IVa 
IVa 
IVa 
IVa 
IVa 
3 
RH 
RH 
RF 
12 
13 
14 
AG, ML, LM, TET, TMP 
AG, ML, LM, TET, TMP 
AG, ML, LM, TET, TMP 
t011 
t011 
t011 
ND 
ND 
398 
IVa 
IVa 
IVa 
a
 LF: left-front; LH: left-hind; RH: right-hind; RF: right-front 427 
b
 AG: all aminoglycosides tested; LM: lincomycin; ML: all macrolides tested; TET: 428 
tetracycline; TMP: trimethoprim  429 
c
 ND: not determined 430 
 431 
